Efficacy of orally administered superfine dispersed lentinan (β-1,3-glucan) for the treatment of advanced colorectal cancer

Anticancer Research

Volumn 29, Issue 7, 2009, Pages 2611-2617

  Hazama, Shoichi ^a   Watanabe, Seiji ^b   Ohashi, Manabu ^c   Yagi, Masashi ^d   Suzuki, Michinari ^e   Matsuda, Kenji ^f   Yamamoto, Tatsuhito ^g   Suga, Yasuyo ^h   Suga, Tetsuya ^h   Nakazawa, Saburo ⁱ   Oka, Masaaki ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Inoue Hospital   (Japan)

^c NIIGATA UNIVERSITY   (Japan)

^d Public Central Hospital of Matto Ishikawa   (Japan)

^e Shunan City Shin Nanyo Hospital   (Japan)

^f Hashimoto Municipal Hospital   (Japan)

^g Iseikai Tsushimi Hospital   (Japan)

^h AJINOMOTO CO INC   (Japan)

ⁱ Yamashita Hospital   (Japan)

Author keywords

Beta 1,3 glucan; Colorectal cancer; Lentinan; Peripheral blood monocytes; Quality of life; Superfine dispersed lentinan

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; CD14 ANTIGEN; CISPLATIN; DOXIFLURIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GIMERACIL; IRINOTECAN; LENTINAN; LEVOFOLINATE; TEGAFUR; UFT; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG BINDING; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG SAFETY; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOCYTE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LENTINAN; MALE; MIDDLE AGED; QUALITY OF LIFE;

EID: 69249187521     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Chihara G, Maeda YY, Hamuro J, Sakaki T and Fukuoka F: Inhibition of mouse sarcoma 180 by polysaccharide from Lentinus edodes (Berk) Sing. Nature 222: 687-688, 1969.
2. Zakany J, Chihara G and Fachet J: Effect of lentinan on the production of migration inhibitory factor induced by syngeneic tumor in mice. Int J Cancer 26: 783-788, 1980. (Pubitemid 11213234)
3. Suga T, Shiio T, Maeda YY and Chihara G: Antitumor activity of lentinan in murine syngeneic and autochthonous hosts and its suppressive effect on 3-methylcholanthrene-induced carcinogenesis. Cancer Res 44: 5132-5137, 1984. (Pubitemid 15204477)
4. Ochiai T, Isono K, Suzuki T, Koide Y, Gunji Y, Nagata M and Ogawa N: Effect of immunotherapy with lentinan on patients' survival and immunological parameters in patients with gastric cancer: Results of a multi-centre randomized controlled study. Int J Immunother VIII: 161-169, 1992. (Pubitemid 23023129)
5. Taguchi T: Clinical efficacy of lentinan on patients with stomach cancer - End point results of a four-year follow-up survey. Cancer Detect Prev Suppl 1: 333-349, 1987.
6. Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K and Kumada K: A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: Effect on prolongation of survival and improvement of quality of life. Hepato-Gastroenterol 46: 2662-2668, 1999. (Pubitemid 29454163)
7. Maeda YY and Chihara G: The effects of neonatal thymectomy on the antitumor activity of lentinan, carboxymethylpachymaran and zymosan, and their effects on various immune responses. Int J Cancer 11: 153-161, 1973.
8. Hamuro J, Rollinghoff M and Wagner H: Induction of cytotoxic peritoneal exudates cells by T-cell immune adjuvants of the β(1→3) glucan-type lentinan and its analogues. Immunology 39: 551-559, 1980.
9. Yoshino S, Tabata T, Hazama S, Iizuka N, Yamamoto K, Hirayama M, Tangoku A and Oka M: Immunoregulatory effects of the antitumor polysaccharide lentinan on Th1/Th2 balance in patients with digestive cancer. Anticancer Res 20: 4707-4712, 2000. (Pubitemid 32127715)
10. Thornton B P, Vetvicka V, Pitman M, Goldman R C and Ross G D: Analysis of the sugar specificity and molecular location of the β-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J Immunol 156: 1235-1246, 1996. (Pubitemid 26048122)
11. Brown G D, Taylor P R, Reid D M, Willment J A, Williams D L, Pomares L M, Wong S Y C and Gordon S: Dectin-1 is a major β-glucan receptor on macrophages. J Exp Med 196: 407-412, 2002.
12. Gantner BN, Simmons RM, Canavera SJ, Akira S and Underhill DM: Collaborative induction of inflammatory responses by dectin-1 and toll-like receptor 2. J Exp Med 197: 1107-1117, 2003. (Pubitemid 36570066)
13. Hamuro J, Murata Y, Suzuki M, Takatsuki F and Suga T: The triggering and healing of tumor stromal inflammatory reactions regulated by oxidative and reductive macrophages. Gann Monograph Cancer Res 48: 153-164, 1999. (Pubitemid 30781212)
14. Murata Y, Shimamura T, Tagami T, Takatsuki F and Hamuro J: The skewing to Th1 induced by lentinan is directed through the distinctive cytokine production by macrophages with elevated intracellular glutathione content. Int Immunopharmac 2: 673-689, 2002. (Pubitemid 34246367)
15. Murata Y, Shimamura T and Hamuro J: The polarization of T(h)1/T(h)2 balance is dependent on the intracellular thiol redox status of macrophages due to the distinctive cytokine production. Int Immunol 14: 201-212, 2002. (Pubitemid 34144744)
16. Yamada J, Hamuro J, Hatanaka H, Hamabata K and Kinoshita S: Alleviation of seasonal allergic symptoms with superfine β-1,3-glucan - A randomized study. J Allergy Clin Immunol 119: 1119-1126, 2007. (Pubitemid 46654185)
17. Shen J, Ren H, Tomiyama MC, Suga Y, Suga T Kuwano Y, Iiai T, Hatakeyama K and Abo T: Potentiation of intestinal immunity by micellary mushroom extracts. Biomed Res 28: 71-77, 2007. (Pubitemid 46845916)
18. Suga Y, Matsunaga Y, Sato Y, Murata M and Suga T: The importance of size for antitumor effects of beta-glucan. Biotherapy 19: 273-278, 2005 (in Japanese with English abstract). (Pubitemid 40874347)
19. Trotti A, Colevas A D, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman C N and Rubin P: CTCAE v3.0: development of a comprehensive grading system for the adverse events of cancer treatment. Semin Radiat Oncol 13: 176-181, 2003. (Pubitemid 36962641)
20. Kurihara M, Shimizu H, Tsuboi K, Kobayashi K, Murakami M, Eguchi K and Shimozuma K: Development of quality of life questionnaire in Japan: quality of life assessment of cancer patients receiving chemotherapy. Psycho-oncology 8: 355-363, 1999. (Pubitemid 29417490)
21. Lorish CD and Maisiak R: The face scale - a brief, nonverbal method for assessing patient mood. Arthritis Rheum 29: 906-909, 1986.
22. Kishida E, Sone Y, Shibata S and Misaki A: Preparation and immunochemical characterization of antibody to branched β-(1-3)-D-glucan of Volvariella volvasea, and its use in studies of antitumor actions. J Agric Biol Chem 53: 1849-1859, 1989.
23. Rosati G, Cordio S, Caputo G, Condorelli S, Germano D, Mattina M, Amadio P, Reggiardo G and Manzione L: Phase II trial of a biweekly regimen of fluorouracil and leucovorin plus irinotecan in patients with previously untreated advanced gastric cancer. J Chemother 19: 570-576, 2007. (Pubitemid 350182305)
24. Bouzid K, Khalfallah S, Tujakowski J, Piko B, Purkalne G, Plate S, Padrik P, Serafy M, Pshevloutsky E M and Boussard B: A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer. Ann Oncol 14: 1106-1114, 2003. (Pubitemid 36950176)
25. Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oza A, Skovsgaard T, Munier S and Martin C: Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3617-3627, 2002. (Pubitemid 34983221)
26. Shirao K, Hoff P M, Ohtsu A, Loehrer P J, Hyodo I, Wadler S, Wadleigh R G, O'Dwyer P J, Muro K, Yamada Y, Boku N, Nagashima F and Abbruzzese J L: Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer - Joint United States and Japan study of UFT/LV. J Clin Oncol 22: 3466-3474, 2004. (Pubitemid 41103652)
27. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A and Arai K, for the ACTS-GC Group: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357: 1810-1820, 2007.
28. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H and Takeuchi M: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial) - a phase III trial. Lancet Oncol 9: 215-221, 2008.
29. James H D: Redox modulation of chemotherapy-induced tumor cell killing and normal tissue toxicity. J Natl Cancer Inst 98: 223-225, 2006.
30. Alexandre J, Nicco C, Chereau C, Laurent A, Weill B, Goldwasser F and Batteux F: Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J Natl Cancer Inst 98: 236-244, 2006. (Pubitemid 43264707)
31. Mantovani G, Maccio A, Madeddu C, Mura L, Gramignano G, Lusso M R, Murgia V, Camboni P, Ferreli L, Mocci M and Massa E: The impact of different antioxidant agents alone or in combination on reactive oxgen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites - Correlation with disease progression. Free Radical Res 37: 213-223, 2003. (Pubitemid 36124348)
32. Graves E, Hitt A, Pariza M W, Cook M E and McCarthy D O: Conjugated linoleic acid preserves gastrocnemius muscle mass in mice bearing the colon-26 adenocarcinoma. Res Nurs Health 28: 48-55, 2005. (Pubitemid 40223377)
33. Hamuro J, Kikuchi T, Takatsuki F and Suzuki M: Cancer cell progression and chemoimmunotherapy - Dual effects in the induction of resistance to therapy. Br J Cancer 73: 465-471, 1996. (Pubitemid 26055314)
34. Aou S, Ma J and Hori T: Effects of lentinan on food intake and plasma calcium level. Biotherapy 5: 1728-1731, 1991 (in Japanese with English abstract).
35. Suzuki M, Takatsuki F, Maeda Y Y, Hamuro J and Chihara G: Antitumor and immunological activity of lentinan in comparison with LPS. Int J Immunopharmacol 16: 462-468, 1996. (Pubitemid 24192369)
36. Strassmann G, Masui Y, Chizzonite R and Fong M: Mechanisms of experimental cancer cachexia: Local involvement of IL-1 in colon-26 tumor. J Immunol 150: 2341-2345, 1993. (Pubitemid 23127479)